

Tjalf Ziemssen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1820711/tjalf-ziemssen-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

356
papers

8,226
citations

47
h-index

75
g-index

416
ext. papers

10,183
ext. citations

4.9
avg, IF

6.57
L-index

#	Paper	IF	Citations
356	Stroke-induced immunodepression: experimental evidence and clinical relevance. <i>Stroke</i> , 2007 , 38, 770-367	36.7	354
355	Identifying prodromal Parkinson β disease: pre-motor disorders in Parkinson β disease. <i>Movement Disorders</i> , 2012 , 27, 617-26	7	339
354	Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. <i>Nature</i> , 2016 , 530, 349-53	50.4	203
353	Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. <i>Brain</i> , 2002 , 125, 2381-91	11.2	199
352	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 175-187	27.4	172
351	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. <i>Lancet Neurology, The</i> , 2013 , 12, 756-67	24.1	163
350	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology, The</i> , 2017 , 16, 189-199	24.1	156
349	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology, The</i> , 2018 , 17, 405-415	24.1	150
348	Non-motor dysfunction in Parkinson β disease. <i>Parkinsonism and Related Disorders</i> , 2007 , 13, 323-32	3.6	147
347	The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. <i>Journal of Experimental Medicine</i> , 2004 , 199, 185-97	16.6	141
346	Optimizing treatment success in multiple sclerosis. <i>Journal of Neurology</i> , 2016 , 263, 1053-65	5.5	111
345	Multiple sclerosis beyond EDSS: depression and fatigue. <i>Journal of the Neurological Sciences</i> , 2009 , 277 Suppl 1, S37-41	3.2	109
344	A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity. <i>Nature Immunology</i> , 2017 , 18, 654-664	19.1	104
343	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology, The</i> , 2017 , 16, 271-281	24.1	101
342	Glatiramer acetate: mechanisms of action in multiple sclerosis. <i>Autoimmunity Reviews</i> , 2007 , 6, 469-75	13.6	100
341	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E2973-82	11.5	98
340	Cardiovascular autonomic dysfunction in Parkinson β disease. <i>Journal of the Neurological Sciences</i> , 2010 , 289, 74-80	3.2	97

339	The norepinephrine system shows information-content specific properties during cognitive control - Evidence from EEG and pupillary responses. <i>NeuroImage</i> , 2017 , 149, 44-52	7.9	85
338	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 851-8	5.5	84
337	Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1792-9	5	83
336	Optimizing therapy early in multiple sclerosis: An evidence-based view. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 460-469	4	77
335	Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. <i>Movement Disorders</i> , 2009 , 24, 2136-42	7	76
334	Molecular biomarkers in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2019 , 16, 272	10.1	75
333	Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. <i>Therapeutic Advances in Neurological Disorders</i> , 2017 , 10, 343-359	6.6	69
332	The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). <i>Autoimmunity Reviews</i> , 2005 , 4, 460-7	13.6	69
331	Therapeutic decisions in multiple sclerosis: moving beyond efficacy. <i>JAMA Neurology</i> , 2013 , 70, 1315-24	17.2	67
330	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. <i>JAMA Neurology</i> , 2016 , 73, 1089-98	17.2	67
329	Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e555	9.1	63
328	Use and acceptance of electronic communication by patients with multiple sclerosis: a multicenter questionnaire study. <i>Journal of Medical Internet Research</i> , 2012 , 14, e135	7.6	63
327	Glatiramer acetate: mechanisms of action in multiple sclerosis. <i>International Review of Neurobiology</i> , 2007 , 79, 537-70	4.4	62
326	Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e228	9.1	58
325	The role of TH17 cells in multiple sclerosis: Therapeutic implications. <i>Autoimmunity Reviews</i> , 2020 , 19, 102647	13.6	57
324	Risk-benefit assessment of glatiramer acetate in multiple sclerosis. <i>Drug Safety</i> , 2001 , 24, 979-90	5.1	56
323	Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. <i>BMC Neurology</i> , 2016 , 16, 124	3.1	55
322	Perceptions on the value of bodily functions in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2018 , 137, 356-362	3.8	54

321	Spectral Analysis of Heart Rate Variability: Time Window Matters. <i>Frontiers in Neurology</i> , 2019 , 10, 545	4.1	53
320	The norepinephrine system affects specific neurophysiological subprocesses in the modulation of inhibitory control by working memory demands. <i>Human Brain Mapping</i> , 2017 , 38, 68-81	5.9	53
319	Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. <i>Health and Quality of Life Outcomes</i> , 2008 , 6, 67	3	53
318	Influence of ECG sampling frequency on spectral analysis of RR intervals and baroreflex sensitivity using the EUROBAVAR data set. <i>Journal of Clinical Monitoring and Computing</i> , 2008 , 22, 159-68	2	52
317	Psychoneuroimmunology--cross-talk between the immune and nervous systems. <i>Journal of Neurology</i> , 2007 , 254 Suppl 2, I18-11	5.5	51
316	Demands on response inhibition processes determine modulations of theta band activity in superior frontal areas and correlations with pupillometry - Implications for the norepinephrine system during inhibitory control. <i>NeuroImage</i> , 2017 , 157, 575-585	7.9	50
315	Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 411-8	5.5	50
314	CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. <i>Bone Marrow Transplantation</i> , 2010 , 45, 1489-96	4.4	49
313	Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 752-8	5	49
312	Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination. <i>Molecular Psychiatry</i> , 2015 , 20, 880-888	15.1	48
311	Review: Patient-reported outcomes in multiple sclerosis care. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 33, 61-66	4	47
310	The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System-A Review. <i>Frontiers in Neurology</i> , 2019 , 10, 53	4.1	47
309	Clinical outcome measures in multiple sclerosis: A review. <i>Autoimmunity Reviews</i> , 2020 , 19, 102512	13.6	47
308	Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. <i>Journal of the Neurological Sciences</i> , 2005 , 233, 109-12	3.2	47
307	Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. <i>Autoimmunity Reviews</i> , 2017 , 16, 355-376	13.6	46
306	The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. <i>BMC Neurology</i> , 2015 , 15, 93	3.1	44
305	Symptom management in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011 , 311 Suppl 1, S48-52	3.2	42
304	Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. <i>Therapeutic Advances in Neurological Disorders</i> , 2016 , 9, 250-63	6.6	40

303	Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires. <i>Journal of Immunology</i> , 2005 , 175, 69-81	5.3	40
302	A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. <i>Journal of Neurology</i> , 2021 , 268, 1210-1221	5.5	40
301	Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015 , 122, 419-25	4.3	37
300	Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. <i>Journal of Neuroinflammation</i> , 2017 , 14, 41	10.1	36
299	The norepinephrine system and its relevance for multi-component behavior. <i>NeuroImage</i> , 2017 , 146, 1062-1070	7.9	36
298	Valsalva manoeuvre in patients with different Parkinsonian disorders. <i>Journal of Neural Transmission</i> , 2009 , 116, 875-80	4.3	36
297	Facilitated defensive coping, silent ischaemia and ECG left-ventricular hypertrophy: the SABPA study. <i>Journal of Hypertension</i> , 2012 , 30, 543-50	1.9	36
296	Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. <i>Journal of Neural Transmission</i> , 2008 , 115, 1527-36	4.3	36
295	Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients. <i>Journal of Neural Transmission</i> , 2013 , 120 Suppl 1, S61-6	4.3	35
294	Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neural Transmission</i> , 2010 , 117, 69-76	4.3	35
293	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 68, 409-11	9.4	35
292	Natalizumab during pregnancy and lactation. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1627-1634	5	34
291	Defensive coping facilitates higher blood pressure and early sub-clinical structural vascular disease via alterations in heart rate variability: the SABPA study. <i>Atherosclerosis</i> , 2013 , 227, 391-7	3.1	34
290	Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1649-1660	4	33
289	Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. <i>Movement Disorders</i> , 2010 , 25, 315-24	7	33
288	Multiple sclerosis registries in Europe - An updated mapping survey. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 171-178	4	33
287	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. <i>CNS Drugs</i> , 2020 , 34, 185-196	6.7	32
286	Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. <i>Journal of Autoimmunity</i> , 2018 , 90, 116-131	15.5	32

285	New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. <i>Journal of Neuroinflammation</i> , 2016 , 13, 164	10.1	32
284	Digital Twins for Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021 , 12, 669811	8.4	32
283	Static posturography in aging and Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 2012 , 4, 20	5.3	31
282	Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. <i>Atherosclerosis Supplements</i> , 2009 , 10, 39-43	1.7	31
281	Adult polyglucosan body disease: a postmortem correlation study. <i>Neurology</i> , 2003 , 61, 263-5	6.5	31
280	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1809-1818	5	31
279	Brain-immune communication psychoneuroimmunology of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 6-21	5	30
278	Autonomic dysfunction in different subtypes of multiple system atrophy. <i>Movement Disorders</i> , 2008 , 23, 1766-72	7	30
277	Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 48-56	5	30
276	Cortisol awakening response is linked to disease course and progression in multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e60647	3.7	29
275	The sensory channel of presentation alters subjective ratings and autonomic responses toward disgusting stimuli-Blood pressure, heart rate and skin conductance in response to visual, auditory, haptic and olfactory presented disgusting stimuli. <i>Frontiers in Human Neuroscience</i> , 2013 , 7, 510	3.3	29
274	Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis. <i>Psychoneuroendocrinology</i> , 2011 , 36, 1505-12	5	29
273	Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System. <i>Interactive Journal of Medical Research</i> , 2016 , 5, e2	2.1	29
272	A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. <i>Journal of Neurology</i> , 2014 , 261, 2101-11	5.5	28
271	A new line immunoassay for the multiparametric detection of antiganglioside autoantibodies in patients with autoimmune peripheral neuropathies. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1109, 256-64	6.5	28
270	The effects of venlafaxine on autonomic functions in healthy volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 687-91	1.7	28
269	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. <i>CNS Drugs</i> , 2018 , 32, 1159-1171	6.7	28
268	The role of phasic norepinephrine modulations during task switching: evidence for specific effects in parietal areas. <i>Brain Structure and Function</i> , 2018 , 223, 925-940	4	26

267	Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial. <i>Journal of Alternative and Complementary Medicine</i> , 2009 , 15, 507-11	2.4	26
266	Autonomic dysfunction in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2008 , 23, 2083-9	7	26
265	Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014 , 1, e33	9.1	25
264	Greater cardiovascular reactivity to a cold stimulus is due to higher cold pain perception in black Africans: the Sympathetic Activity and Ambulatory Blood Pressure in Africans (SABPA) study. <i>Journal of Hypertension</i> , 2012 , 30, 2416-24	1.9	25
263	Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e548	9.1	24
262	Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020 , 10, 5941	4.9	24
261	Autonomic function and cerebral autoregulation in patients undergoing carotid endarterectomy. <i>Circulation Journal</i> , 2010 , 74, 2139-45	2.9	23
260	Multiple sclerosis and the autonomic nervous system. <i>Journal of Neurology</i> , 2006 , 253 Suppl 1, I21-5	5.5	23
259	Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). <i>Frontiers in Neurology</i> , 2020 , 11, 632	4.1	23
258	Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up. <i>Frontiers in Neurology</i> , 2018 , 9, 1071	4.1	23
257	Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients. <i>Frontiers in Immunology</i> , 2018 , 9, 2669	8.4	23
256	Sudomotor Testing of Diabetes Polyneuropathy. <i>Frontiers in Neurology</i> , 2018 , 9, 803	4.1	23
255	Anodal tDCS affects neuromodulatory effects of the norepinephrine system on superior frontal theta activity during response inhibition. <i>Brain Structure and Function</i> , 2019 , 224, 1291-1300	4	22
254	Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT) [®] . <i>Neurology and Therapy</i> , 2015 , 4, 125-36	4.6	22
253	Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1729-1739	5	22
252	Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 2199-2212	5.3	22
251	Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study. <i>BMC Neurology</i> , 2017 , 17, 11	3.1	21
250	Trigonometric regressive spectral analysis: an innovative tool for evaluating the autonomic nervous system. <i>Journal of Neural Transmission</i> , 2013 , 120 Suppl 1, S27-33	4.3	21

249	Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. <i>Movement Disorders</i> , 2007 , 22, 2123-6	7	21
248	Recognition and treatment of autonomic disturbances in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 1189-203	4.3	20
247	Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 369-378	4.1	20
246	Seizures associated with zoledronic acid for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1955-9	5.6	20
245	A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. <i>Journal of Medical Internet Research</i> , 2020 , 22, e16932	7.6	20
244	Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine. <i>CNS Drugs</i> , 2019 , 33, 61-79	6.7	20
243	Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. <i>European Journal of Endocrinology</i> , 2014 , 170, 349-57	6.5	19
242	Modern communication technology skills of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1240-1	5	19
241	Determination of baroreflex sensitivity during the modified Oxford maneuver by trigonometric regressive spectral analysis. <i>PLoS ONE</i> , 2011 , 6, e18061	3.7	19
240	Functional energetics of CD4 ⁺ -cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. <i>PLoS ONE</i> , 2011 , 6, e18506	3.7	19
239	Trigonometric regressive spectral analysis reliably maps dynamic changes in baroreflex sensitivity and autonomic tone: the effect of gender and age. <i>PLoS ONE</i> , 2010 , 5, e12187	3.7	19
238	Treatment of dysautonomia in extrapyramidal disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2010 , 3, 53-67	6.6	19
237	Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. <i>Proteomics - Clinical Applications</i> , 2009 , 3, 1273-87	3.1	19
236	Baroreceptor sensitivity, cardiovascular responses and ECG left ventricular hypertrophy in men: the SABPA study. <i>Blood Pressure</i> , 2011 , 20, 355-61	1.7	19
235	Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. <i>CNS Drugs</i> , 2020 , 34, 973-988	6.7	19
234	Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016 , 1,	0	19
233	Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 247-255	4.1	19
232	Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod. <i>BMC Neurology</i> , 2016 , 16, 129	3.1	19

231	Management of fingolimod in clinical practice. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115 Suppl 1, S60-4	2	18
230	Intensified monitoring of circadian blood pressure and heart rate before and after intravitreal injection of bevacizumab: preliminary findings of a pilot study. <i>International Ophthalmology</i> , 2009 , 29, 213-24	2.2	18
229	On the interrelation of 1/ neural noise and norepinephrine system activity during motor response inhibition. <i>Journal of Neurophysiology</i> , 2019 , 121, 1633-1643	3.2	17
228	Improving patient-physician dialog: commentary on the results of the MS Choices survey. <i>Patient Preference and Adherence</i> , 2012 , 6, 143-52	2.4	17
227	Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS). <i>BMC Neurology</i> , 2016 , 16, 109	3.1	17
226	How minimal variations in neuronal cytoskeletal integrity modulate cognitive control. <i>NeuroImage</i> , 2019 , 185, 129-139	7.9	17
225	Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020 , 11, 56	8.4	16
224	Patients' preferences for involvement in the decision-making process for treating diabetic retinopathy. <i>BMC Ophthalmology</i> , 2017 , 17, 139	2.3	16
223	Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells. <i>Atherosclerosis Supplements</i> , 2013 , 14, 107-13	1.7	16
222	Differentiating societal costs of disability worsening in multiple sclerosis. <i>Journal of Neurology</i> , 2020 , 267, 1035-1042	5.5	16
221	Adrenal medullary dysfunction as a feature of obesity. <i>International Journal of Obesity</i> , 2017 , 41, 714-721	5.5	15
220	Effects of acute and chronic stress on the L-arginine nitric oxide pathway in black and white South Africans: the sympathetic activity and ambulatory blood pressure in Africans study. <i>Psychosomatic Medicine</i> , 2013 , 75, 751-8	3.7	15
219	Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis. <i>Journal of Neurology</i> , 2005 , 252 Suppl 5, v38-45	5.5	15
218	Graves' disease after treatment with alemtuzumab for multiple sclerosis. <i>Hormones</i> , 2015 , 14, 148-53	3.1	15
217	Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1337-1346	5	15
216	Predictors of response to opicinumab in acute optic neuritis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1154-1162	5.3	15
215	Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ). <i>Journal of Neurology</i> , 2016 , 263, 1969-83	5.5	14
214	Autonomic responses to stress in Black versus Caucasian Africans: the SABPA study. <i>Psychophysiology</i> , 2012 , 49, 454-61	4.1	14

213	Rapidly progressive course of very late onset multiple sclerosis presenting with Parkinsonism: case report. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 245-9	5	14
212	A Digital Patient Portal for Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 400	4.1	13
211	Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL. <i>PLoS ONE</i> , 2017 , 12, e0173353	3.7	13
210	QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients. <i>Journal of Neurology</i> , 2016 , 263, 784-91	5.5	13
209	Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study. <i>Experimental & Translational Stroke Medicine</i> , 2013 , 5, 7		13
208	Education research: cognitive performance is preserved in sleep-deprived neurology residents. <i>Neurology</i> , 2009 , 73, e99-e103	6.5	13
207	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211039648	6.6	13
206	Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. <i>Journal of Central Nervous System Disease</i> , 2019 , 11, 1179573519831997	4.4	12
205	Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. <i>Frontiers in Neurology</i> , 2019 , 10, 253	4.1	12
204	Data Collection in Multiple Sclerosis: The MSDS Approach. <i>Frontiers in Neurology</i> , 2020 , 11, 445	4.1	12
203	Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. <i>Journal of Neuroinflammation</i> , 2017 , 14, 172	10.1	12
202	Immunomodulatory treatments and cognition in MS. <i>Acta Neurologica Scandinavica</i> , 2016 , 134 Suppl 200, 55-9	3.8	12
201	Cutaneous Autonomic Pilocomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson Disease (CAPTURE PD): Protocol for a Multicenter Study. <i>Frontiers in Neurology</i> , 2017 , 8, 212	4.1	12
200	Pupillary responses to intranasal trigeminal and olfactory stimulation. <i>Journal of Neural Transmission</i> , 2009 , 116, 885-9	4.3	12
199	The effects of lorazepam on skin conductance responses to aversive stimuli in healthy subjects. <i>Clinical Autonomic Research</i> , 2007 , 17, 160-4	4.3	12
198	Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. <i>PLoS ONE</i> , 2015 , 10, e0138243	3.7	12
197	The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study. <i>Journal of Medical Internet Research</i> , 2020 , 22, e17921	7.6	12
196	A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101861	4	12

195	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1866-1876	5	12
194	Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 21512-21518	11.5	12
193	Attenuated brain-derived neurotrophic factor and hypertrophic remodelling: the SABPA study. <i>Journal of Human Hypertension</i> , 2015 , 29, 33-9	2.6	11
192	Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA. <i>Neurotherapeutics</i> , 2018 , 15, 190-199	6.4	11
191	Time matters - acute stress response and glucocorticoid sensitivity in early multiple sclerosis. <i>Brain, Behavior, and Immunity</i> , 2014 , 41, 82-9	16.6	11
190	Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis. <i>Frontiers in Neuroscience</i> , 2017 , 11, 540	5.1	11
189	Cardiovascular autonomic testing in extrapyramidal disorders. <i>Journal of the Neurological Sciences</i> , 2011 , 310, 129-32	3.2	11
188	Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 721-31	6.2	11
187	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 1756286420982134	6.6	11
186	Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice. <i>Brain Sciences</i> , 2021 , 11,	3.4	11
185	Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418803248	6.6	11
184	Immunoabsorption with regenerating systems in neurological disorders --A single center experience. <i>Atherosclerosis Supplements</i> , 2015 , 18, 119-23	1.7	10
183	Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol. <i>BMC Neurology</i> , 2020 , 20, 95	3.1	10
182	Balance Testing in Multiple Sclerosis-Improving Neurological Assessment With Static Posturography?. <i>Frontiers in Neurology</i> , 2020 , 11, 135	4.1	10
181	Autonomic Dysfunction in Wilson's Disease: A Comprehensive Evaluation during a 3-Year Follow Up. <i>Frontiers in Physiology</i> , 2017 , 8, 778	4.6	10
180	Autonome Dysfunktion beim idiopathischen Parkinson-Syndrom und der Multisystematrophie. <i>Aktuelle Neurologie</i> , 2006 , 33, 385-393		10
179	Time for Change - Evolution of Real-world Evidence Outcome Measures in Multiple Sclerosis Exemplified by Fingolimod. <i>European Neurological Review</i> , 2015 , 9, 136	0.5	10
178	Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis. <i>Advances in Experimental Medicine and Biology</i> , 2004 , 541, 111-34	3.6	10

177	Acute hyperlipidemia but not hyperhomocysteinemia impairs reflex regulation of the cardiovascular system. <i>Atherosclerosis Supplements</i> , 2015 , 18, 8-15	1.7	9
176	Effects of the PPAR α agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial. <i>Heart and Vessels</i> , 2015 , 30, 286-95	2.1	9
175	Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. <i>BMC Neurology</i> , 2016 , 16, 98	3.1	9
174	Dual-Tasking in Multiple Sclerosis - Implications for a Cognitive Screening Instrument. <i>Frontiers in Human Neuroscience</i> , 2018 , 12, 24	3.3	9
173	ActiGait implantable drop foot stimulator in multiple sclerosis: a new indication. <i>Journal of Neurosurgery</i> , 2017 , 126, 1685-1690	3.2	9
172	LDL apheresis improves deranged cardiovascular modulation in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2010 , 213, 212-7	3.1	9
171	The cold hand sign in multiple system atrophy: skin perfusion revisited. <i>Journal of Neural Transmission</i> , 2010 , 117, 475-9	4.3	9
170	Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA. <i>JMIR Research Protocols</i> , 2020 , 9, e19598	2	9
169	Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (Prospective phArmacoeconomic cohOrt evaluation) Noninterventional Study Protocol. <i>JMIR Research Protocols</i> , 2016 , 5, e23	2	9
168	Impedimetric Microfluidic Sensor-in-a-Tube for Label-Free Immune Cell Analysis. <i>Small</i> , 2021 , 17, e2002549	4.9	9
167	Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756285617748845	6.6	8
166	Multi-component relaxation in clinically isolated syndrome: Lesion myelination may predict multiple sclerosis conversion. <i>NeuroImage: Clinical</i> , 2018 , 20, 61-70	5.3	8
165	Perspectives of an innovative ophthalmological technology: optical coherence tomography (OCT)--what should be of interest to the neurologist?. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115 Suppl 1, S55-9	2	8
164	Treatment of dysautonomia in extrapyramidal disorders. <i>Journal of Neurology</i> , 2011 , 258, S339-45	5.5	8
163	Treatment strategies for nonmotor manifestations of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 773-84	4	8
162	Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1719-1728	5	8
161	Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study. <i>European Journal of Neurology</i> , 2020 , 27, 2531-2538	6	8
160	The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice. <i>Frontiers in Neuroscience</i> , 2020 , 14, 582046	5.1	8

159	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021 , 12, 701752	8.4	8
158	Exploring individual multiple sclerosis lesion volume change over time: Development of an algorithm for the analyses of longitudinal quantitative MRI measures. <i>NeuroImage: Clinical</i> , 2019 , 21, 101623	5.3	8
157	Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting. <i>Therapeutic Advances in Chronic Disease</i> , 2019 , 10, 2040622319835136	4.9	7
156	Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study. <i>Patient Preference and Adherence</i> , 2020 , 14, 869-880	2.4	7
155	Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study. <i>Journal of Molecular Medicine</i> , 2019 , 97, 1263-1271	5.5	7
154	36 Months Pangaea: A 5-Year Non-Interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients In Daily Clinical Practice. <i>Value in Health</i> , 2015 , 18, A749	3.3	7
153	Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects. <i>Cells</i> , 2021 , 10,	7.9	7
152	Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 39, 101893	4	7
151	Serum biomarkers of cerebral cellular stress after self-limiting tonic clonic seizures: An exploratory study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021 , 85, 1-5	3.2	7
150	Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis. <i>Journal of Molecular Medicine</i> , 2019 , 97, 1547-1555	5.5	6
149	How the depth of processing modulates emotional interference - evidence from EEG and pupil diameter data. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2019 , 19, 1231-1246	3.5	6
148	Different responses of the retinal and cutaneous microcirculation to transient dysmetabolic conditions. <i>Atherosclerosis Supplements</i> , 2015 , 18, 1-7	1.7	6
147	Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis. <i>Pharmacoeconomics</i> , 2020 , 38, 883-892	4.4	6
146	Visual Feedback and Postural Control in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
145	An Innovative Technique to Assess Spontaneous Baroreflex Sensitivity with Short Data Segments: Multiple Trigonometric Regressive Spectral Analysis. <i>Frontiers in Physiology</i> , 2018 , 9, 10	4.6	6
144	Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1553-1556	4	6
143	Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate. <i>BMC Neurology</i> , 2015 , 15, 189	3.1	6
142	Potential side effect of high-dose corticosteroid relapse treatment: acute generalized exanthematous pustulosis (AGEP). <i>Multiple Sclerosis Journal</i> , 2009 , 15, 275-7	5	6

141	Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101859	4	6
140	Hes3 expression in the adult mouse brain is regulated during demyelination and remyelination. <i>Brain Research</i> , 2016 , 1642, 124-130	3.7	6
139	Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419892077	6.6	6
138	Should We Use Clinical Tools to Identify Disease Progression?. <i>Frontiers in Neurology</i> , 2020 , 11, 628542	4.1	6
137	Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration. <i>Frontiers in Neurology</i> , 2020 , 11, 391	4.1	5
136	Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures. <i>Frontiers in Neurology</i> , 2017 , 8, 703	4.1	5
135	Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease. <i>BMC Neurology</i> , 2014 , 14, 126	3.1	5
134	Development of A Screening Tool to Support Identification of Patients With Secondary Progressive Multiple Sclerosis (Spms). <i>Value in Health</i> , 2015 , 18, A763	3.3	5
133	Confirmed Disability Improvement In Patients With Active Multiple Sclerosis Treated With Fingolimod Versus Brace: A Matched Comparison of Treatments From The Pangaea And Pearl Registry Studies. <i>Value in Health</i> , 2015 , 18, A750	3.3	5
132	Metabolomic distinction of microvascular effects of lipoprotein apheresis--a pilot study. <i>Atherosclerosis Supplements</i> , 2013 , 14, 143-9	1.7	5
131	Ethnic-specific correlations of visfatin with circulating markers of endothelial inflammation and function. <i>Obesity</i> , 2009 , 17, 2210-5	8	5
130	Modernes Therapiemanagement zur Verbesserung der Therapie mit Interferon β mit MSDS 3D. <i>Aktuelle Neurologie</i> , 2012 , 39, S2-S5		5
129	Wandel in aktueller Bewertung neuer Wirkstoffe erfordert Erhebung pharmakoökonomischer Daten: Behandlungszufriedenheit von Fingolimod (Gilenya) im Vergleich zu Erstlinientherapeutika bei Patienten mit Multipler Sklerose (PANGAEA und PEARL). <i>Aktuelle Neurologie</i> , 2012 , 39, 385-385		5
128	Neurofilament light chain in serum is significantly increased in chorea-acanthocytosis. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 28-31	3.6	5
127	Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101503	4	5
126	A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose-Possible Predictors of Cardiac Outcomes. <i>Frontiers in Neurology</i> , 2020 , 11, 818	4.1	5
125	CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study. <i>Brain Pathology</i> , 2021 , 31, e12969	6	5
124	Laquinimod in the treatment of relapsing remitting multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 701-9	5.5	5

123	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , 2020 , 9, 443-457	4.6	4
122	Defensive active coping facilitates chronic hyperglycaemia and endothelial dysfunction in African men: the SABPA study. <i>International Journal of Cardiology</i> , 2013 , 168, 999-1005	3.2	4
121	Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease. <i>Atherosclerosis Supplements</i> , 2013 , 14, 135-41	1.7	4
120	Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment. <i>BMC Neurology</i> , 2017 , 17, 62	3.1	4
119	Dynamic formation of macular microcysts independent of vitreous traction changes. <i>Neurology</i> , 2015 , 84, 436-7	6.5	4
118	A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 83-4	4	4
117	Psychoneuroimmunology - psyche and autoimmunity. <i>Current Pharmaceutical Design</i> , 2012 , 18, 4485-8	3.3	4
116	In vitro modulation of steroid 5alpha-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia. <i>Steroids</i> , 2001 , 66, 521-8	2.8	4
115	The need for a strategic therapeutic approach: multiple sclerosis in check.. <i>Therapeutic Advances in Chronic Disease</i> , 2022 , 13, 20406223211063032	4.9	4
114	Digital Biomarkers in Multiple Sclerosis. <i>Brain Sciences</i> , 2021 , 11,	3.4	4
113	A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm. <i>JMIR Medical Informatics</i> , 2020 , 8, e17592	3.6	4
112	Gender disparities in health resource utilization in patients with relapsing-remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420960274	6.6	4
111	Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 81	7.3	4
110	6-sulpho LacNAc(+) dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system. <i>Neuropathology and Applied Neurobiology</i> , 2016 , 42, 394-8	5.2	4
109	Mutually reinforcing effects of genetic variants and interferon- α therapy for pulmonary arterial hypertension development in multiple sclerosis patients. <i>Pulmonary Circulation</i> , 2019 , 9, 2045894019872192	2.7	4
108	Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?. <i>Hormone and Metabolic Research</i> , 2019 , 51, 779-784	3.1	4
107	Fear of falling and falls in people with multiple sclerosis: A literature review. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 47, 102609	4	4
106	Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT Autoinjector: A Prospective Observational Cohort Study. <i>Frontiers in Neurology</i> , 2021 , 12, 643126	4.1	4

105	Using Machine Learning Algorithms for Identifying Gait Parameters Suitable to Evaluate Subtle Changes in Gait in People with Multiple Sclerosis. <i>Brain Sciences</i> , 2021 , 11,	3.4	4
104	Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 1756286421993999	6.6	4
103	How to Implement Adherence-Promoting Programs in Clinical Practice? A Discrete Choice Experiment on Physicians' Preferences. <i>Patient Preference and Adherence</i> , 2020 , 14, 267-276	2.4	3
102	Attenuated NOx responses and myocardial ischemia, a possible risk for structural vascular disease in African men: the SABPA study. <i>Journal of Human Hypertension</i> , 2014 , 28, 438-43	2.6	3
101	Mehr als dokumentieren: computerunterstütztes Patientenmanagement. <i>Der Neurologe Und Psychiater</i> , 2013 , 14, 57-62	0	3
100	Untersuchung zur Genauigkeit der Abtastung von EKG-Signalen für eine nachfolgende Spektralanalyse kontinuierlich gemessener RR-Intervalle im Schlaflabor. <i>Somnologie</i> , 2006 , 10, 53-60	2	3
99	Phospholipase A2 degradation products modulate epithelial and stromal 5alpha-reductase activity of human benign prostatic hyperplasia in vitro. <i>Prostate</i> , 2002 , 50, 4-14	4.2	3
98	Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.. <i>Journal of Neurology</i> , 2022 , 1	5.5	3
97	Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis. <i>Cells</i> , 2021 , 10,	7.9	3
96	Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients. <i>Frontiers in Neurology</i> , 2021 , 12, 637107	4.1	3
95	B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	3
94	Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	3
93	Improving Digital Patient Care: Lessons Learned from Patient-Reported and Expert-Reported Experience Measures for the Clinical Practice of Multidimensional Walking Assessment. <i>Brain Sciences</i> , 2021 , 11,	3.4	3
92	Comparison of baroreflex sensitivity estimated from ECG R-R and inter-systolic intervals obtained by finger plethysmography and radial tonometry. <i>Journal of Neural Transmission</i> , 2016 , 123, 481-90	4.3	3
91	Differential longitudinal changes of neuronal and glial damage markers in anorexia nervosa after partial weight restoration. <i>Translational Psychiatry</i> , 2021 , 11, 86	8.6	3
90	Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
89	Profiles of eHealth Adoption in Persons with Multiple Sclerosis and Their Caregivers. <i>Brain Sciences</i> , 2021 , 11,	3.4	3
88	Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. <i>Neurological Research and Practice</i> , 2021 , 3, 44	3.2	3

87	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211032803	5	3
86	Dem MS-Phänotyp auf der Spur. <i>Der Neurologe Und Psychiater</i> , 2019 , 20, 33-36	0	2
85	Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod. <i>Clinical Pharmacology in Drug Development</i> , 2018 , 7, 217-221	2.3	2
84	Ein Jahr Alemtuzumab – Was haben wir in der Praxis gelernt? Experten-Erfahrungsaustausch zur Therapie der Multiplen Sklerose. <i>Aktuelle Neurologie</i> , 2015 , 42, 535-541		2
83	Pangaea 2.0: State Of The Art Multiple Sclerosis Patient Management In Daily Clinical Practice. A New 3-Year Observational Study Of Patients Receiving Fingolimod. <i>Value in Health</i> , 2015 , 18, A686	3.3	2
82	Insulin is a key determinant of elevated retinal arteriolar flicker response in insulin-resistant individuals. <i>Diabetologia</i> , 2015 , 58, 2154-60	10.3	2
81	Effects of the Peroxisome Proliferator-Activated Receptor- α Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial. <i>Cardiology</i> , 2015 , 131, 165-71	1.6	2
80	Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 754-755	4	2
79	Intravitreal bevacizumab and blood pressure: does safe mean safe enough?. <i>Acta Ophthalmologica</i> , 2007 , 85, 573-4; author reply 574-5		2
78	Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations.. <i>Movement Disorders</i> , 2022 ,	7	2
77	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020 , 6, 2055217320972137	2	2
76	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061343	5	2
75	Peripheral nerve field stimulation in medically refractory trigeminal neuralgia attributed to multiple sclerosis. <i>Journal of Neurosurgery</i> , 2020 , 134, 1244-1250	3.2	2
74	Therapieziele und Therapiemanagement bei schubförmigremittierender Multipler Sklerose. <i>Nervenheilkunde</i> , 2015 , 34, 915-923	0.3	2
73	The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102523	4	2
72	Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021 , 12, 650530	4.1	2
71	CSF and Serum Biomarkers of Cerebral Damage in Autoimmune Epilepsy. <i>Frontiers in Neurology</i> , 2021 , 12, 647428	4.1	2
70	The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2

69	Internationale Brain Health Initiative und Multiple Sklerose. <i>DGNeurologie</i> , 2020 , 3, 107-115	0.2	2
68	Cost of illness in multiple sclerosis by disease characteristics - A review of reviews. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 1-19	2.2	2
67	The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources.. <i>International Journal of MS Care</i> , 2021 , 23, 261-268	2.3	2
66	Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence. <i>Neurodegenerative Disease Management</i> , 2019 , 9, 1-2	2.8	1
65	Response to: Kobayashi et al.: "Erythroblast appearance associated with natalizumab" Multiple Sclerosis and Related Disorders 2019. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 32, 114-115	4	1
64	Autonome Small-Fiber-Neuropathien. <i>Neurologie Up2date</i> , 2019 , 2, 51-65	0.1	1
63	Evozierte Potenziale - noch up to date?. <i>Der Neurologe Und Psychiater</i> , 2020 , 21, 28-34	0	1
62	On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Device-A Proof of Concept Study in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
61	Der Patient als Experte. <i>Der Neurologe Und Psychiater</i> , 2020 , 21, 33-36	0	1
60	Properties of lower level processing modulate the actions of the norepinephrine system during response inhibition. <i>Biological Psychology</i> , 2020 , 152, 107862	3.2	1
59	Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" Multiple Sclerosis and Related Disorders 2017. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 68-69	4	1
58	Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418759895	6.6	1
57	Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson's disease. <i>Scientific Reports</i> , 2017 , 7, 7012	4.9	1
56	Neuroborreliosis during natalizumab treatment in multiple sclerosis. <i>Neurology</i> , 2013 , 81, 1012-4	6.5	1
55	What can we learn from failed clinical trials in multiple sclerosis?. <i>Journal of Neurology</i> , 2008 , 255 Suppl 6, 97-101	5.5	1
54	Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. <i>Frontiers in Immunology</i> , 2021 , 12, 715195	8.4	1
53	Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not.. <i>Scientific Reports</i> , 2022 , 12, 1446	4.9	1
52	Automated Analysis of the Two-Minute Walk Test in Clinical Practice Using Accelerometer Data. <i>Brain Sciences</i> , 2021 , 11,	3.4	1

51	The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study (Preprint)		1
50	Response to: S. Sega-Jazbec et al.: "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis" <i>Multiple Sclerosis and Related Disorders</i> 2017. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 177-178	4	1
49	Local endothelial dysfunction does not affect global endothelial function. <i>Vasa - European Journal of Vascular Medicine</i> , 2015, 44, 277-84	1.9	1
48	Why Cognitive-Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice. <i>Frontiers in Neurology</i> , 2020, 11, 905	4.1	1
47	Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in an Ultra-Rare Disease		1
46	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. <i>Journal of Medical Internet Research</i> , 2021, 23, e29558	7.6	1
45	Kipptischuntersuchung Schritt für Schritt. <i>Neurologie Up2date</i> , 2019, 2, 339-346	0.1	1
44	Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis". <i>Multiple Sclerosis Journal</i> , 2020, 26, 742-743	5	1
43	A possible role of the norepinephrine system during sequential cognitive flexibility - Evidence from EEG and pupil diameter data. <i>Cortex</i> , 2020, 128, 22-34	3.8	1
42	How to reduce the delay of diagnosing secondary progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 646-647	5	1
41	Relation of retinal and hippocampal thickness in patients with amnesic mild cognitive impairment and healthy controls. <i>Brain and Behavior</i> , 2021, 11, e02035	3.4	1
40	Delayed retinal vein recovery responses indicate both non-adaptation to stress as well as increased risk for stroke: the SABPA study. <i>Cardiovascular Journal of Africa</i> , 2021, 32, 5-16	0.7	1
39	Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing". <i>Multiple Sclerosis Journal</i> , 2018, 24, 820-822	5	1
38	Innovation in Digital Education: Lessons Learned from the Multiple Sclerosis Management MasterB Program. <i>Brain Sciences</i> , 2021, 11,	3.4	1
37	Wie messe ich das Unsichtbare?. <i>Der Neurologe Und Psychiater</i> , 2021, 22, 29-34	0	1
36	Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2013-2024	5.3	1
35	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2021, 135245852111061335	5	1
34	Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies.. <i>Frontiers in Neuroscience</i> , 2021, 15, 791670	5.1	1

33	Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.. <i>Wiener Medizinische Wochenschrift</i> , 2022 , 1	2.9	1
32	Nocturnal blood pressure, 3-methoxy-4-hydroxyphenylglycol and carotid intima-media thickness: The SABPA study. <i>Heart Lung and Circulation</i> , 2013 , 22, 917-23	1.8	0
31	Umsetzung der Nationalen VersorgungsLeitlinie (NVL) zur Therapie des Diabetes mellitus Typ 2 in diabetologischen Schwerpunktpraxen. <i>Diabetes Aktuell</i> , 2017 , 15, 257-270	0	0
30	Moderne Immuntherapie der multiplen Sklerose. <i>Aktuelle Neurologie</i> , 2008 , 35, 160-168		0
29	Time-On-Task Effects on Working Memory Gating Processes-A Role of Theta Synchronization and the Norepinephrine System.. <i>Cerebral Cortex Communications</i> , 2022 , 3, tgac001	1.9	0
28	Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. <i>Frontiers in Immunology</i> , 2021 , 12, 715195	8.4	0
27	A role of the norepinephrine system or effort in the interplay of different facets of inhibitory control.. <i>Neuropsychologia</i> , 2022 , 166, 108143	3.2	0
26	Neural and glial damage markers in women after long-term weight-recovery from anorexia nervosa. <i>Psychoneuroendocrinology</i> , 2022 , 135, 105576	5	0
25	No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 567659	5.7	0
24	Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose. <i>DGNeurologie</i> , 2021 , 4, 319-326	0.2	0
23	Dissonance in Music Impairs Spatial Gait Parameters in Patients with Parkinson Disease. <i>Journal of Parkinson Disease</i> , 2021 , 11, 363-372	5.3	0
22	Wissensstand von Patienten und Gesundheitsberufen über Diabetes-bedingte Augenerkrankungen (Risikofaktoren, Früherkennung und Behandlung). <i>Diabetologie Und Stoffwechsel</i> , 2018 , 13, 263-269	0.7	0
21	Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study. <i>Frontiers in Neurology</i> , 2021 , 12, 620758	4.1	0
20	Serum neurofilament light chain levels are associated with stroke severity and functional outcome in patients undergoing endovascular therapy for large vessel occlusion. <i>Journal of the Neurological Sciences</i> , 2021 , 429, 118063	3.2	0
19	Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022 , 8, 20552173221085741	2	0
18	Limited Time from the Diabetes Patients Perspective: Need for Conversation with the Eye Specialist. <i>Ophthalmologica</i> , 2016 , 236, 154-158	3.7	
17	Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis". <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 57-58	4	
16	Psychometric Analyses to Inform Item Reduction and Evaluate Sensitivity of the Early Mobility Impairment Questionnaire for Multiple Sclerosis. <i>Value in Health</i> , 2014 , 17, A403	3.3	

15	PP.41.04. <i>Journal of Hypertension</i> , 2015 , 33, e501	1.9
14	Physician-patient communication skills: e-tools. <i>Neurodegenerative Disease Management</i> , 2015 , 5, 51-3	2.8
13	Neue Perspektiven eines modernen Untersuchungsverfahrens. <i>Der Neurologe Und Psychiater</i> , 2012 , 13, 69-75	0
12	Posttranslationale Regulationsmöglichkeiten membrangebundener Enzyme am Beispiel der prostatistischen 5 β -Reduktase. <i>Laboratoriums Medizin</i> , 1999 , 23, 723-724	
11	Daten sammeln aus der Praxis: der Weg zum digitalen MS-Zwilling. <i>Der Neurologe Und Psychiater</i> , 2021 , 22, 30-36	0
10	MS-Dokumentation, -Register und -Management 2018 , 435-447	
9	MS-Dokumentation, MS-Register und MS-Management 2015 , 447-459	
8	Die Anwendung von Multi-Touch-Gesten in Patientenmanagementsystemen. <i>Xpert Press</i> , 2013 , 301-315	
7	Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211004634	2
6	Letter to the editor regarding "Therapeutic drug monitoring of natalizumab". <i>Multiple Sclerosis Journal</i> , 2020 , 26, 741-742	5
5	Comparative study of microvascular function: Forearm blood flow versus dynamic retinal vessel analysis. <i>Clinical Physiology and Functional Imaging</i> , 2021 , 41, 42-50	2.4
4	Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018 , 91, 849-850	6.5
3	Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart Injector: Results of the Prospective Cohort Study REBIFLECT.. <i>Advances in Therapy</i> , 2022 , 1	4.1
2	Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. <i>Therapeutic Advances in Neurological Disorders</i> , 2022 , 15, 175628642210903	6.6
1	Transparent Quality Optimization for Machine Learning-Based Regression in Neurology. <i>Journal of Personalized Medicine</i> , 2022 , 12, 908	3.6